NCT05363280View on ClinicalTrials.gov

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Small Cell Lung Cancer
Interventions
DRUG

AL8326 low dose group

Taken AL3826 at low dose orally

DRUG

AL8326 middle dose group

Taken AL3826 at middle dose orally

DRUG

AL8326 high dose group

Taken AL3826 at high dose orally

Trial Locations (6)

35294

University of Alabama at Birmingham, Birmingham

44195

Cleveland Clinic, Cleveland

60611

Northwestern University, Chicago

63130

Siteman Cancer Center, Washington University, St Louis

Unknown

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Universitario Ramón Y Cajal, Madrid

Sponsors
All Listed Sponsors
lead

Advenchen Pharmaceuticals, LLC.

INDUSTRY

NCT05363280 - Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC | Biotech Hunter | Biotech Hunter